Showing results (71-80 of 326) with videos related to
Sort By:
Pageof 33
Current Drug Safety|June 19, 2009
Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medicationsLeslie CitromeExpert Review of Neurotherapeutics|December 24, 2008
Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence?Leslie CitromeExpert Opinion on Drug Metabolism & Toxicology|November 2, 2010
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinionLeslie CitromeTherapeutics and Clinical Risk Management|June 1, 2013
Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agentsLeslie CitromeCNS Drugs|September 25, 2013
A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approachLeslie CitromeCNS Spectrums|January 4, 2017
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?Leslie CitromeThe Journal of Clinical Psychiatry|March 4, 2014
Unmet needs in the treatment of schizophrenia: new targets to help different symptom domainsLeslie CitromePatient Preference and Adherence|December 18, 2009
Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injectionLeslie CitromeCNS Spectrums|December 24, 2025
Introducing a special collection of CME articles about long-acting injectable antipsychoticsLeslie CitromePageof 33